Clinical trials: Ocular Discomfort
Refractive Error
Formula Identification (FID) 114657 in Contact Lens Wearers
The purpose of this study is to evaluate the thickness of the pre-lens tear lipid layer after 2 hours of lens wear with use of FID 114657 compared to saline control.
- Trial name
- NCT02293538
- Testing
- FID 114657 eye drops (10 ml), Saline control eye drops (15 ml), Habitual contact lenses
- Volunteers
- 234 people
- Sponsor
- Alcon Research
Visual Acuity
An Investigation of the Impact of Localized Topical Anesthesia of the Ocular Surface on End-of-day Contact Lens Discomfort
This is a controlled, randomized, subject-masked, 3x3 crossover, non-dispensing, contralateral study. Twenty subjects will be recruited based on their scores (with their habitual lenses) from the Contact Lens Dry Eye…
- Trial name
- NCT03733899
- Testing
- Local Anesthesia
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Vision Care, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 2 (NCT02819284)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 62 sites in United States
- Volunteers
- 909 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Disease
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
The purpose of this study was to determine if difluprednate ophthalmic emulsion is effective in reducing the ocular symptoms of dry eye disease, as measured by a global Visual Analog Scale (VAS) discomfort score.
- Trial name
- NCT01276223
- Testing
- Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
- Where
- United States
- Volunteers
- 722 people, healthy volunteers welcome
- Sponsor
- Alcon Research
Dry Eye, Graft-versus-host-disease
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
The purpose of this Phase 1/2 study is to compare the safety and tolerability of four times a day (QID) dosing of a non-preserved topical ocular drop formulation of 10 vol/vol % and 30 vol/vol % of FD hPL to vehicle control eye…
- Conditions
- Dry Eye, Graft-versus-host-disease, Ocular Discomfort
- Trial name
- NCT03414645
- Testing
- CAM-101 10%, Vehicle Control, CAM-101 30%
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cambium Bio Limited
Ocular Discomfort
Safety and Efficacy of 2 Concentrations of Lubricin vs Sodium Hyaluronate in Ocular Discomfort After Refractive Surgery.
The objective of this study was to evaluate tolerability, safety, permanence on the ocular surface and efficacy of Lubricin (20 and 50 μg/mL) eye drops vs Sodium Hyaluronate (Vismed®) 0.18% eye drops in patients with ocular…
- Trial name
- NCT03031327
- Testing
- Lubricin 20µg/ml, Lubricin 50µg/ml, Sodium hyaluronate 0.18%
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Dompé Farmaceutici S.p.A
Ocular Discomfort
A Study to Evaluate the Clinical Performance of a Novel Multipurpose Solution
The objective of this study is to evaluate the clinical performance of Bausch \& Lomb investigational Multi-Purpose Solution compared to Ciba Vision Multi-Purpose Solution when used by wearers of silicone hydrogel or Group IV…
- Trial name
- NCT01024751
- Testing
- Bausch & Lomb Multi-Purpose Solution, Ciba's Multi-Purpose Solution
- Where
- United States
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- STRIDE 1 (NCT02813265)
- Testing
- KPI-121 0.25% Ophthalmic Suspension, Vehicle of KPI-121 0.25% Ophthalmic Suspension
- Where
- 60 sites in United States
- Volunteers
- 918 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye, Dry Eye Syndromes
Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye
Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time.
- Trial name
- NCT03417505
- Testing
- Scleral lenses treated with Tangible Hydra-PEG, Untreated scleral lenses
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tangible Science
Ocular Dryness
Clinical Investigation on the Use of Ophthalmic Solution Based on Sodium Hyaluronate in Treatment of Eye Discomfort
The purpose of this study is to assess the performance and safety resulting from the treatment of an ophthalmic solution for the ocular discomfort and in particular in presence of ocular dryness.
- Trial name
- NCT05777798
- Testing
- Hyalistil Bio PF
- Where
- 2 sites in Italy
- Volunteers
- 28 people
- Sponsor
- SIFI SpA
Dry Eye
LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
The purpose of this study is to evaluate the efficacy of LME636 compared to vehicle in the reduction of ocular symptoms and to evaluate the safety and tolerability of LME636, when administered topically for up to 42 days, in…
- Trial name
- NCT02365519
- Testing
- LME636 ophthalmic solution, LME636 Vehicle
- Volunteers
- 514 people
- Sponsor
- Alcon, a Novartis Company
Blepharitis
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to vehicle (placebo) in subjects with signs and symptoms of inflammatory meibomian gland disease.
- Trial name
- Maui (NCT02218489)
- Testing
- KPI-121, Vehicle
- Where
- 8 sites in United States
- Volunteers
- 206 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease
The primary purpose of this study is to determine the efficacy and safety of KPI-121 0.25% ophthalmic suspension compared to vehicle (placebo) in subjects who have a documented clinical diagnosis of dry eye disease.
- Trial name
- Kauai (NCT02188160)
- Testing
- KPI-121
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Eyes Dry Chronic
ESBA105 in Patients With Severe Dry Eye
The purpose of this study was to evaluate the efficacy of ESBA105 over vehicle in reducing the ocular symptoms of dry eye disease, as measured by a mean global Visual Analog Scale (VAS) discomfort score.
- Trial name
- NCT01338610
- Testing
- ESBA105 ophthalmic solution, ESBA105 vehicle
- Where
- United States
- Volunteers
- 334 people
- Sponsor
- Alcon Research
Ocular Discomfort
A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery
The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.
- Trial name
- NCT03035864
- Testing
- rhNGF, Vehicle
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Dompé Farmaceutici S.p.A
Meibomian Gland Dysfunction (MGD), Contact Lens Discomfort (CLD)
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
SOVS2019-070 is a single-center study of AZR-MD-001 ointment and AZR-MD-001 vehicle in patients with Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD).
- Trial name
- NCT03972501
- Testing
- AZR-MD-001 Vehicle, AZR-MD-001 Active Dose
- Where
- Australia
- Volunteers
- 26 people
- Sponsor
- Azura Ophthalmics
Dry Eye Syndrome
Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
The purpose of this study was to determine if Sodium Hyaluronate, 0.18% is effective in treating the signs and symptoms of dry eye disease.
- Trial name
- NCT01382225
- Testing
- Sodium Hyaluronate Ophthalmic Solution, 0.18%, Vehicle
- Volunteers
- 1,936 people
- Sponsor
- Alcon Research
Lid Wiper Epitheliopathy
Lid Wiper Epitheliopathy Trial
The purpose of this study is to evaluate the effect of contact lens lubricity on lid wiper epitheliopathy (LWE) in symptomatic contact lens wearers.
- Trial name
- NCT01870856
- Testing
- Spectacles, Delefilcon A contact lenses, Etafilcon A contact lenses
- Volunteers
- 187 people
- Sponsor
- Alcon Research